76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Embecta Corp
Closed
SectorHealthcare
11.65 2.28
Overview
Share price change
24h
Min
11.62
Max
11.75
Income | 50M 24M |
|---|---|
Sales | -2.9M 259M |
P/E Sector Avg | 11.562 38.156 |
Dividend yield | 6.13 |
Profit margin | 9.073 |
Employees | 2,000 |
EBITDA | 24M 63M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +53.78% upside |
Dividend yield Sector Avg | 6.13% 2.50% |
|---|---|
Next Earnings | 8 Aug 2025 |
Next Dividend date | 12 Sept 2025 |
Next Ex Dividend date | 26 Aug 2025 |
Market Cap | -139M 601M |
|---|---|
Previous open | 9.37 |
Previous close | 11.65 |
News Sentiment
By Acuity
50%
50%
164 / 375 Healthcare
Embecta Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Embecta Corp Forecast
Price Target
By TipRanks
53.78% upside
12 Months Forecast
Average 17.5 USD 53.78%
High 25 USD
Low 12 USD
Based on 4 Wall Street analysts offering 12 month price targets forEmbecta Corp - Dist in the last 3 months.
Sentiment
By Acuity
164 / 375 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Embecta Corp
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
